News
Judges announced for groundbreaking dementia tech prize

Nine longevity experts from around the world have been named by Challenge Works as judges of the groundbreaking Longitude Prize on Dementia.
Innovation prize specialists Challenge Works has announced details of the judging panel for the Longitude Prize on Dementia, naming nine judges including representatives from The Alan Turing Institute and University of Cambridge.
The Longitude Prize on Dementia is a £4.34 million prize to drive the creation of personalised, technology-based tools that are co-created with people living with the early stages of dementia, helping them live independent, more fulfilled lives and being able to do the things they enjoy.
The challenge prize aims to incentivise the creation of AI and machine-learning based technologies that provide personalised solutions to help people with dementia to live longer, higher quality lives at home, learning from a person’s data about what they do, who they know and what’s most important to them as an individual.
Once the judging panel has assessed the candidates 23 teams will be selected to receive £80,000 Discovery Awards and expert capacity-building support to develop their solutions.
Five will receive an additional £300,000 in 2024 to develop a validated prototype or product with one going on to win the £1 million first prize in 2026.
Judging the entries and guiding the selection of the 23 teams making it through to the Discovery Award stage of the prize are:
- John T O’Brien, Department of Psychiatry, Dementia Researcher at The University of Cambridge, UK
- Dawn Brooker, Emeritus Professor and former Director of the University of Worcester Association for Dementia Studies, University of Worcester, UK
- Mary Furlong, President and CEO of Mary Furlong Associates, a global leader in consultancy for entrepreneurs and innovators in the longevity ecosystem, USA
- Dawne Garrett, Consultant Nurse, previously Lead for Older People & Dementia Care, Royal College of Nursing, UK
- Eric Kihlstrom, Chair of Open Age and Aging2.0 Ambassador, UK
- Prof. Mugendi K. M’Rithaa, Industrial Designer, Educator and Researcher at Machakos University, Kenya
- Nic Palmarini, Director at National Innovation Centre Ageing, UK
- Simon Reeve, Director of Innovation at The Alan Turing Institute, UK
- Prof. Cathy Treadaway, Professor of Creative Practice at Cardiff School of Art and Design, UK
Eric Kihlstrom, Longitude Prize on Dementia Judge and Ambassador for Aging 2.0, commented: “After the initial effects of the pandemic lockdowns, ageing has become a ‘white hot’ area for innovation, and Alzheimer’s falls into that category. This prize is focused on improving the quality of life for people living with dementia and their carers. If we can do that, we can keep people living with dementia out of institutional care, and we can help people live the lives they want to.
“If you’re an innovator with an inspirational idea, you sometimes don’t know where to go and don’t know what’s already been done. If we, as judges, can make that journey faster and help innovators to focus on the critical questions – it can make a big difference.”
People with lived experience of dementia (people living with dementia, carers and former carers) will be involved at every judging stage of the Longitude Prize on Dementia.
The Lived Experience Advisory Panel (LEAP) will be made up of international representatives and will review designs, ideas and give insights into how technologies could support and enable independent living for a person with a diagnosis of dementia.
Dawne Garrett, former Lead for Older People & Dementia Care, Royal College of Nursing, added: “The outcome of this prize has potential to make a tangible and lasting change to how people living with early-stage dementia approach this disease. There is no doubt that the kind of technology we hope to see will uproot lazy assumptions about what people living with dementia can and can’t do, and ensure that people can live in a dignified and fulfilling way.”
Applications to the prize remain open until 26 January 2023.
For more information on the Longitude Prize on Dementia visit dementia.longitudeprize.org
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.













